SEC Form 4 · accession 0001193125-26-295089
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Noah Goodman
Officer — Chief Business Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 6:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 1, 2026 | S | 3,389 | $114.29 | D | 47,179 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
- F2This number includes 373 shares acquired under the Registrant's employee stock purchase plan.